Zobrazeno 1 - 10
of 32
pro vyhledávání: ''
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-8 (2021)
BMC Cancer
BMC Cancer
Background Regorafenib has shown promising results as a second-line therapy for patients with hepatocellular carcinoma (HCC) who progressed on sorafenib. Although there have been several data regarding the efficacy of sequential therapy with sorafeni
Autor:
Takuma Kagami, Mihoko Yamade, Takahiro Suzuki, Shinya Tani, Satoshi Baba, Takahisa Furuta, Hiroaki Miyajima, Junko Murai, Moriya Iwaizumi, Yasushi Hamaya, Yves Pommier, Haruhiko Sugimura, Satoshi Osawa, Takahiro Uotani, Ken Sugimoto
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-11 (2020)
BMC Cancer
BMC Cancer
Background Schlafen 11 (SLFN11) was recently identified as a dominant determinant of sensitivity to DNA-targeting agents including platinum-based drugs. SLFN11 also reportedly enhances cellular radiosensitivity. In this study, we examined the prognos
Autor:
Chenlu Zhang, Xiaojing Xu, Shengchao Wu, Wei Guo, Fei Huang, Yiyi Yu, Tianshu Liu, Mengling Liu, Li Liang, Minna Shen
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-10 (2020)
BMC Cancer
BMC Cancer
Background The aim of this study was to explore the utility of circulating free DNA (cfDNA) in the evaluation of clinical tumor burden and survival in Chinese patients with metastatic colorectal cancer (mCRC) and to preliminarily summarize some metas
Autor:
Takanori Hazeyama, Mikio Nakamura, Kazuyoshi Uchihashi, Yujo Kawashita, Shigehisa Aoki, Hiroki Moriuchi, Masaki Tateishi, Junzo Yamaguchi, Takashi Ueda
Publikováno v:
BMC Cancer
BMC Cancer, Vol 21, Iss 1, Pp 1-11 (2021)
BMC Cancer, Vol 21, Iss 1, Pp 1-11 (2021)
Background Interactions between adipocyte and breast cancer (BC) cells have yet to be fully elucidated. Here we investigated the prognostic impact of marginal adipose tissue invasion in both luminal breast cancer (HR+/HER2-) and triple-negative breas
Autor:
Linda T. Vahdat, Erhan Berrak, Sharon Wilks, Yaohua He, Shannon Puhalla, Joyce O'Shaughnessy, Kristi McIntyre, Lee S. Schwartzberg
Publikováno v:
BMC Cancer, Vol 19, Iss 1, Pp 1-10 (2019)
BMC Cancer
BMC Cancer
Background Eribulin mesylate is a nontaxane microtubule dynamics inhibitor approved for second-line (European Union) or third-line (United States) treatment of metastatic breast cancer. Two phase 2 single trials, evaluating first-line eribulin as mon
Publikováno v:
BMC Cancer, Vol 18, Iss 1, Pp 1-8 (2018)
BMC Cancer
BMC Cancer
Background Hepatocellular carcinoma (HCC) is a common cancer worldwide, with a poor prognosis. Most patients are diagnosed at advanced stages and are only eligible for palliative therapy. Therefore, this study aimed to evaluate the safety and efficac
Autor:
Ryota Tamura, Yukina Morimoto, Kenzo Kosugi, Mizuto Sato, Yumiko Oishi, Ryo Ueda, Ryogo Kikuchi, Hideaki Nagashima, Tetsuro Hikichi, Shinobu Noji, Yutaka Kawakami, Hikaru Sasaki, Kazunari Yoshida, Masahiro Toda
Publikováno v:
BMC Cancer
BMC Cancer, Vol 20, Iss 1, Pp 1-10 (2020)
BMC Cancer, Vol 20, Iss 1, Pp 1-10 (2020)
Background The expression of vascular endothelial growth factor (VEGF)-A/ VAGF receptors (VEGFRs) signaling plays a pivotal role in the tumor angiogenesis and the development of the immunosuppressive tumor microenvironment in glioblastomas. We have p
Autor:
Naoyuki Sone, Takashi Niwa, Hiroshige Yoshioka, Tadashi Ishida, Takashi Ogura, Toshihide Yokoyama, Satoshi Ikeda, Akimasa Sekine, Akihiro Nishiyama, Satoshi Ikeo, Mitsunori Morita
Publikováno v:
BMC Cancer, Vol 17, Iss 1, Pp 1-8 (2017)
BMC Cancer
BMC Cancer
Background There have been few data on the chemotherapy in elderly advanced non-small cell lung cancer (NSCLC) patients with poor performance status (PS), and usefulness of chemotherapy for such patients remains unclear. The objective of this study w
Publikováno v:
BMC Cancer
BMC Cancer, Vol 19, Iss 1, Pp 1-8 (2019)
BMC Cancer, Vol 19, Iss 1, Pp 1-8 (2019)
Background The prognostic role of serum alkaline phosphatase (ALP) has been found in several kinds of solid malignant tumor, but has never been extensively discussed in pancreatic cancer, especially through the application of dynamic survival model w
Autor:
Emmanuel S. Antonarakis, Theodore L. DeWeese, Channing J. Paller, Iyah Chen, Tomasz M. Beer, Stephen Greco, Curtiland Deville, Elisabeth I. Heath, Stanley L. Liauw, Matthew P. Deek, Samuel R. Denmeade, Daniel E. Spratt, Matt Gaver, Hao Wang, Arthur Y. Hung, Danny Y. Song, Mario A. Eisenberger, Tamara L. Lotan, Riley McIntyre, Jason W.D. Hearn, Phuoc T. Tran, Roche Kapoor, Mark C. Markowski, Neil Desai, Michael A. Carducci, Megan N. Kummerlowe, Natasha Raman
Publikováno v:
BMC Cancer
BMC Cancer, Vol 19, Iss 1, Pp 1-10 (2019)
BMC Cancer, Vol 19, Iss 1, Pp 1-10 (2019)
Background In men with a rising PSA following radical prostatectomy, salvage radiation therapy (SRT) offers a second chance for cure. Hormonal therapy can be combined with SRT in order to increase prostate tumor control, albeit with associated higher